Vertex Pharmaceuticals and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-Stem, to optimize production of Vertex’s cell therapies for type 1 diabetes, or T1D. TreeFrog and Vertex will collaborate to scale-up TreeFrog’s process to produce and amplify cells for Vertex’s T1D therapies. TreeFrog’s proprietary technology platform, C-Stem, is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D. The technology will enhance Vertex’s ability to generate large amounts of fully differentiated cells for its portfolio of T1D cell therapies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
- Vertex Pharmaceuticals announces advancements in suzetrigine pain program
- Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study
- Biotech Alert: Searches spiking for these stocks today
- Alpine Immune Sciences downgraded to Market Perform from Outperform at Leerink
